Ischemic and Reperfused Myocardium Detected with Technetium-99m-Nitroimidazole

Journal of Nuclear Medicine

Volumn 37, Issue 5, 1996, Pages 761-765

  Fukuchi, Kazuki ^a   Kusuoka, Hideo ^a   Watanabe, Yoshiyuki ^a   Fujiwara, Toshiyuki ^a   Nishimura, Tsunehiko ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Ischemia; Reperfusion; Technetium 99m nitroimidazole

Indexed keywords

DIAGNOSTIC AGENT; DRUG DERIVATIVE; IODOPHENAZONE; NITROIMIDAZOLE DERIVATIVE; OXO[3,3,9,9 TETRAMETHYL 1 (2 NITRO 1H IMIDAZOL 1 YL) 4,8 DIAZAUNDECANE 2,10 DIONEDIOXIMATO]TECHNETIUM TC 99M; PHENAZONE; RADIOACTIVE IODINE; TECHNETIUM; TECHNETIUM COMPLEX;

ANIMAL; ARTICLE; COMPARATIVE STUDY; CORONARY ARTERY BLOOD FLOW; FEMALE; HEART MUSCLE; HEART MUSCLE ISCHEMIA; METABOLISM; PHYSIOLOGY; RAT; SCINTISCANNING; SPRAGUE DAWLEY RAT; STUNNED HEART MUSCLE; TIME;

ANIMALS; ANTIPYRINE; CORONARY CIRCULATION; FEMALE; IODINE RADIOISOTOPES; MYOCARDIAL ISCHEMIA; MYOCARDIAL STUNNING; MYOCARDIUM; NITROIMIDAZOLES; ORGANOTECHNETIUM COMPOUNDS; RATS; RATS, SPRAGUE-DAWLEY; TECHNETIUM; TIME FACTORS;

EID: 0030136701     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. REFERENCES 1. Chapman JD. Hypoxic sensitizers; implications for radiation therapy. N Engl J Med 1979;301:1429-1432.
2. Chapman JD, Franko AJ, Sharplin J. A marker for hypoxic cells in tumors with potential clinical applicability. Br J Cancer 1981;43:546-550.
3. 3H]fluoromisonidazole in ischemic myocardium. J Nucl Med 1989;30:194-201.
4. 18F]fluoromisomdazole. Int J Radiat Oncol Biol Phys 1992;22:199-212.
5. Shelton ME, Dence CS, Hwang DR, Welch MJ, Bergmann SR. Myocardial kinetics of fluorine-18 misonidazole: a marker of hypoxic myocardium. J Nucl Med 1989;30: 351-358.
6. Martin GV, Biskupiak JE, Caldwell JH, Rasey JS, Krohn KA. Characterization of iodovinylmisonidazole as a marker for myocardial hypoxia. J Nucl Med 1993;34:918-924.
7. Kusuoka H, Hashimoto K, Fukuchi K, Nishimura T. Kinetics of a putative hypoxic tissue marker, technetium-99m nitroimidazole (BMS18132I), in normoxic, hypoxic, ischemic and stunned myocardium. J Nucl Med 1994;35:1371-1376.
8. 131I]iodo-antipyrine. Circ Res 1963;12:58-62.
9. Malsky PM, Vokonas PS, Paul SJ, Robbins SL, Hood WB. Autoradiographic measurement of regional blood flow in normal and ischemic myocardium. Am J Physiol 1977;232:H576-H583.
10. 14C]antipyrine. Am J Physiol 1978;234:H59-H66.
11. 11C and [3H]labeled ligands visualized by imaging plates. Neuroreport 1992;3:961-964.
12. Hale SL, Kloner RA. Effect of early coronary artery reperfusion on infarct development in a model of low collateral flow. Cardiovasc Res 1987;21:668-673.
13. Linder KE, Chan YW, Cyr JE, Malley MF, Nowotnik DP, Nunn AD. TcO (PnAO-1-(2-nitroimidazole) [BMS-181321], a new technetium-containing nitroimidazole complex for imaging hypoxia: synthesis, characterization and xanthine oxidase-catalyzed reduction. J Med Chem 1994;37:9-17.
14. 131I-iodide. Int J Appl Radiat Isotopes 1979;30:365-367.
15. Braunwald E, Kloner R. The stunned myocardium: prolonged, postischemic ventricular dysfunction. Circulation 1982;66:1146-1149.
16. Hale SL, Vivaldi MT, Kloner RA. Fluoresent microspheres: a new tool for visualization of ischemic myocardium in rats. Am J Physiol 1986;251:H863-H868.
17. Rasey JS, Grunbaum Z, Magee S, et al. Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells. Radiat Res 1987;111:292-304.
18. Chapman JD, Baer K, Lee J. Characteristics of the metabolism-induced binding of misonidazole to hypoxic mammalian cells. Cancer Res 1983;43:1523-1528.
19. Chan YW, Linder KE, Jayatilak PG, et al. In-vitro studies on the hypoxic retention of a novel technetium-99m-labeled nitroimidazole in rat heart [Abstract]. J Nucl Med 1994;35(Suppl):l8P.
20. 99mTc-labeled nitroheterocycle capable of identification of hypoxia in heart. Biochem Biophys Res Commun 1993;193:1239-1246.
21. 99mTc-nitroimidazole [Abstract]. Circulation 1993;88:I-250.
22. Stone CK, Mulnix T, Nickles RJ, Renstrom B, Nellis SH, Liedtke AJ. Specificity of regional myocardial retention of the technetium-99m nitroimidazole BMS-181321 during myocardial ischemia and reperfusion: lack of retention with injection in reperfusion [Abstract]. Circulation 1994;90:1-368.
23. Wackers FJ, Berman DS, Maddahi J, et al. Technetium-99m-hexakis 2-methoxy-isobutyl isonitrile: human biodistribution, dosimetry, safety and preliminary comparison to thallium-201 for myocardial perfusion imaging. J Nucl Med 1989;30:301-311.
24. 99mTc-hexakis-2-methoxy-2-methylpropylisonitrile imaging for the assessment of myocardial area at risk and the effect of treatment in acute myocardial infarction. Circulation 1989;80:1277-1286.
25. Khaw BA, Strauss HW, Moore R, et al. Myocardial damage delineated by indium-111-antimyosin Fab and technetium-99m-pyrophosphate. J Nucl Med 1987;28:76-82.
26. Morguet AJ, Munz DL, Klein HH, et al. Myocardial distribution of indium-111-antimyosin Fab and technetium-99m-sestamibi in experimental nontransmural infarction. J Nucl Med 1992;33:223-228.